Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Glaukos Corporation

LaserView is involved in eye surgery services, self-described as a reference in this field.

LaserView

Hospital de Olhos Sadalla Amin Ghanem specializes in ophthalmology services, providing a range of medical and surgical care options.

Hospital de Olhos Sadalla Amin Ghanem

AIER Eye Hospital is a global eye care provider with a network of hospitals and centers across multiple countries, offering ophthalmology services and medical education.

AIER Eye Hospital

Glaukos focuses on developing novel therapies for the treatment of ophthalmic diseases, self-described as pioneering new treatments for chronic eye diseases.

Metric
Company Name	Glaukos Corporation	LaserView	Hospital de Olhos Sadalla Amin Ghanem	AIER Eye Hospital
Symbol	GKOS
MSH ID	COM:GLAUKOS	BR:COM:LASERVIEW	BR:COM:SADALLA	COM:AIERCHINA:EN
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Devices	Medical Services	Healthcare	Eye Care and Ophthalmology
Country	US	BR	BR	CN
Stage				Series A
Employee Count	907
Website	glaukos.com	laserview.com.br	sadalla.com.br	en.aierchina.com
LinkedIn
Founders

Metric
Market Cap	6.05B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital		1.45M

Metric
Revenue	314.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit	239.14M
EBITDA	-82.12M
Operating Income	-128.70M
Net Income	-134.66M
EPS	-2.78
Diluted EPS	-2.78
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.77
Operating Profit Margin	-0.36
EBITDA Margin	-0.26
Net Profit Margin	-0.43
Return on Equity	-0.28
Return on Assets	-0.14
Return on Capital Employed	-0.14

COM:GLAUKOS

Glaukos

Last Close

140.83

22/11 21:00

Market Cap

6.05B

Beta: -

Volume Today

549.00K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-34.36
P/B Ratio	9.30
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	21.84
EV Multiple	-44.37

Metric
Days Sales Outstanding	47.28
Days Payables Outstanding	51.43
Days Inventory Outstanding	257.02
Operating Cycle	311.72
Cash Conversion Cycle	259.12
Asset Turnover	0.37

Metric
Operating Cash Flow	-57.76M
Free Cash Flow	-78.01M
Cash Flow to Debt	-0.07
Operating Cash Flow/Sales	-0.08
Free Cash Flow Yield	-0.01

Metric
Cash & Equivalents	93.47M
Accounts Receivable	-3.84M
Inventory	41.99M
Goodwill	66.13M
Debt to Capitalization	0.46
Debt to Assets	0.40
Current Ratio	5.95
Quick Ratio	4.68

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.10
R&D to Revenue	0.46
SG&A to Revenue